Another mechanism of tumor recurrence after CAR-T treatment is thought to be related to abnormal expression of PD-L1 on tumor cells, which mediates immunosuppressive signals, leading to early failure of CAR-T cells and impaired tumor killing function (48) (Figure 3). The gene discussed is CD274; the disease is neoplasm.